<?xml version="1.0" ?>
<GlossaryTerm id="CDR0000410751">
  <TermName>Pegasys</TermName>
  <TermPronunciation>(PEH-guh-sis)</TermPronunciation>
  <TermDefinition>
    <DefinitionText>A drug used to treat hepatitis C infections. It is also being studied in the treatment and prevention of cancer. It is a cytokine that is modified in the laboratory. It is a type of biological response modifier. Also called peginterferon alfa-2a.</DefinitionText>
    <Dictionary>Cancer.gov</Dictionary>
    <Audience>Patient</Audience>
  </TermDefinition>
  <MediaLink ref="CDR0000713142" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;Pegasys&quot;" language="en" id="_3"/>
  <MediaLink ref="CDR0000713141" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;Pegasys&quot;" language="es" id="_4"/>
  <SpanishTermName>Pegasys</SpanishTermName>
  <SpanishTermDefinition>
    <DefinitionText>Medicamento usado para tratar la infección por hepatitis C. Asimismo, está en estudio para el tratamiento y la prevención de cáncer. Es una citocina modificada en el laboratorio. Es un tipo de modificador de la respuesta biológica. También se llama peginterferón alfa-2a.</DefinitionText>
    <Dictionary>Cancer.gov</Dictionary>
    <Audience>Patient</Audience>
  </SpanishTermDefinition>
  <DateFirstPublished>2005-03-24</DateFirstPublished>
  <DateLastModified>2007-04-12</DateLastModified>
</GlossaryTerm>
